• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fresenius Kabi recalls sodium acetate injection due to presence of particulate matter

March 7, 2022 By Sean Whooley

Fresenius Kabi logo updatedFresenius Kabi USA announced today that it initiated the voluntary recall of seven lots of its sodium acetate injection.

Lake Zurich, Illinois-based Fresenius Kabi recalled the USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial to the user level due to the presence of particulate matter found in reserve and/or stability sample vials.

According to a news release, microscopic and elemental analyses determined the presence of particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose. The administration of an injectable product containing such particulate matter may result in local irritation or swelling or infection in response to the foreign material.

If the particulate matter reaches the blood vessels, it can travel to various organs and block blood vessels in the heart, lungs or brain, potentially causing stroke and possibly leading to death. To date, Fresenius Kabi has received no adverse event reports for the recalled lots, which were produced and sold in 2020 and 2021.

The company’s sodium acetate injection is indicated as a source of sodium for addition to large-volume IV fluids to prevent or correct low blood-sodium levels in patients with restricted or no oral intake. It can also be used as an additive for preparing specific IV fluid formulas when the needs of a patient can’t be met by standard electrolyte or nutrient solutions.

Fresenius Kabi asked customers and distributors to check their stock immediately and to quarantine and discontinue the use and distribution of affected products. The company is conducting the recall with the knowledge of the FDA.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance Tagged With: freseniuskabi

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS